Home » Publications

Publications

Discover how PEPperPRINT Peptide Microarray products have been used in different fields of research.

Showing most recent

Bacterial inhibitors

Xie, Hua
Jul 2019
Peptides related to certain portions of the arginine deiminase enzyme from the bacterium Streptococcus cristatus are provided that disrupt the formation and composition of biofilms containing the oral pathogen Porphyromonas gingivalis, and also modulate the virulence of P. gingivalis. Pharmaceutical compositions containing such peptides and method of using the same are disclosed.

Combination therapy using inhibitors of human growth and differentiation factor 15 (gdf-15) and immune checkpoint blockers

Wischhusen, Jörg; Haake, Markus; Dummer, Reinhard; MEHLING, Matthias; SCHÄFER, Tina; SELLE, Martina
May 2019

Anti-Trail Antibodies and Methods of Use

Boico, Olga; Tzaban, Salit; Oved, Kfir; Cohen-Dotan, Assaf; Eden, Eran
May 2019
An antibody comprising an antigen recognition domain that binds specifically the extracellular domain of TNF-related apoptosis-inducing ligand (TRAIL) between amino acids 95-155 and/or amino acids 190-210 is disclosed. Uses thereof are also disclosed.

ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF

Wiestner, Adrian U.; Skarzynski, Martin W.; Lindorfer, Margaret A.; Taylor, Ronald P.; Rader, Christoph; Vire, Berengere
Feb 2019
An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.

Methods of Selecting Binding Reagents

Mallick, Parag; Egertson, Jarrett
Feb 2019
Methods and systems are provided herein for selecting an affinity reagent which binds a desired peptide epitope in a plurality of sequence contexts. The method relies on obtaining a peptide library, each peptide having the sequence αΧβ, wherein X is the desired peptide epitope, wherein each of a and β comprise an amino acid, using the peptide library to select an affinity reagent.

Novel targets of acinetobacter baumannii

Urwyler, Simon; Haake, Markus; Rudolf, Michael
Jan 2019
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as Acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides. The invention further provides antibodies directed to said antigenic polypeptides.

Soybean Allergy Related Epitopes

Kern, Karolin; Spiegel, Holger; Havenith, Heide; Szardenings, Michael
Nov 2018
The invention relates to a compilation comprising at least five different peptides, each peptide comprising at least one sequence element corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1-354, wherein at least five different epitopes are represented. The invention further relates to an in vitro method for determining a patient’s immune status to soybean allergens, to a method for detecting at least one soybean allergen in a substance and to a method for determining the allergenicity of a soybean variety. Additionally, the invention relates to a kit comprising at least one composition containing a compound comprising at least five different sequence elements each corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1-354, wherein at least five different epitopes are represented. Furthermore, the invention relates to the use of a peptide comprising a sequence element corresponding to an epitope for providing a molecule binding to a protein or peptide comprising the epitope.

Plasmodium Sporozoite Npdp Peptides as Vaccine and Target Novel Malaria Vaccines and Antibodies Binding To

Lanzavecchia, Antonio; Tan, Joshua Hoong Yu; Daubenberger, Claudia; Sack, Brandon
Oct 2018
The present invention provides a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of piasmodium circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or prevention of malaria.

An improved assay for the diagnosis of peanut allergy

Suer, Waltraud; Rohwer, Stefanie; BRIX, Bettina; WEIMANN, Alf
Aug 2018
A diagnostically useful carrier has a polypeptide for specifically capturing an antibody to Ara h 7 isotype 7.0201 in a sample from a subject. A method includes detecting in a sample from a subject the presence or absence of an antibody to Ara h 7 isotype 7.0201. A pharmaceutical composition includes Ara h 7 isotype 7.0201 or a variant thereof.

Gdf-15 as a diagnostic marker to predict the clinical outcome of a treatment with immune checkpoint blockers

WISCHHUSEN, Jörg; Haake, Markus; DUMMER, Reinhard; MEHLING, Matthias
Aug 2018
The present invention relates to methods for predicting the probability of a treatment response of a human cancer patient to an immune checkpoint blocker treatment e.g. with anti PD-1, and to methods for predicting the probability of survival of a human cancer patient following an immune checkpoint blocker treatment, and to apparatuses and kits which can be used in these methods.

Detecting agents and epitopes mapping for detecting glycogen phosphorylase isoenzyme bb

Kapetanovic, Ernest; Yastas, Samir
Jul 2018
Described are an oligopeptide sequence of any of RDHLVGRWIR (E1), IRRFKSSKFGCR (E2), RHLEIIYAINQR (E3). LIIKLVT (E4), WGDRLKVIF (E5), any combination of E1 to E3; or combination of E4 and E5. Further described is a detecting agent for specific detecting glycogen phosphorylase iso-enzyme BB (GPBB), wherein the detecting agent is characterized by specific recognizing and binding to (1) an epitope of the GPBB comprising an oligo-peptide sequence of any of RDHLVGRWIR (E1), IRRFKSSKFGCR (E2), RHLEIIYAINQR (E3) or any combination of E1 to E3; or (2)an epitope of GPBB comprising an oiigo-peptide sequence of LIIKLVT (E4), and/or WGDRLKVIF (E5), or combination of E4 and E5.

Antibodies to human alpha-synuclein

MARTINEZ, Terina N.; DAVE, Kuldip D.; DAS, Sonal
Jun 2018

Quote form